Terms: = Ovarian cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC
76 results:
1. Clinical and multiparametric MRI features for differentiating uterine carcinosarcoma from endometrioid adenocarcinoma.
Chen X; Guo Q; Chen X; Zheng W; Kang Y; Cao D
BMC Med Imaging; 2024 Feb; 24(1):48. PubMed ID: 38373912
[TBL] [Abstract] [Full Text] [Related]
2. Endometrioid adenocarcinoma: combined multiparametric MRI and tumour marker HE4 to evaluate tumour grade and lymphovascular space invasion.
Yue XN; He XY; Wu JJ; Fan W; Zhang HJ; Wang CW
Clin Radiol; 2023 Aug; 78(8):e574-e581. PubMed ID: 37183140
[TBL] [Abstract] [Full Text] [Related]
3. Frequency and distribution of BRCA1/BRCA2 large genomic rearrangements in Turkish population with breast cancer.
Akin Duman T; Ozturk FN
J Hum Genet; 2023 Jul; 68(7):485-490. PubMed ID: 36864289
[TBL] [Abstract] [Full Text] [Related]
4. Clinical characteristic and prognostic factors in high-grade endometrial neuroendocrine carcinoma.
Zhang Z; Wang J; Wu X; Liu Y; Xi X
J Obstet Gynaecol Res; 2022 Aug; 48(8):2180-2188. PubMed ID: 35778826
[TBL] [Abstract] [Full Text] [Related]
5. Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
Lavoro A; Scalisi A; Candido S; Zanghì GN; Rizzo R; Gattuso G; Caruso G; Libra M; Falzone L
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35383859
[TBL] [Abstract] [Full Text] [Related]
6. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers.
Gressel GM; Usyk M; Frimer M; Kuo DYS; Burk RD
PLoS One; 2021; 16(11):e0259188. PubMed ID: 34739493
[TBL] [Abstract] [Full Text] [Related]
8. Volumetric ADC histogram analysis for preoperative evaluation of LVSI status in stage I endometrioid adenocarcinoma.
Ma X; Ren X; Shen M; Ma F; Chen X; Zhang G; Qiang J
Eur Radiol; 2022 Jan; 32(1):460-469. PubMed ID: 34137929
[TBL] [Abstract] [Full Text] [Related]
9. Common DNA methylation dynamics in endometriod adenocarcinoma and glioblastoma suggest universal epigenomic alterations in tumorigenesis.
Karlow JA; Miao B; Xing X; Wang T; Zhang B
Commun Biol; 2021 May; 4(1):607. PubMed ID: 34021236
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
İşçi Bostancı E; Durmuş Y; Duru Çöteli AS; Kayıkçıoğlu F; Boran N
Turk J Med Sci; 2021 Aug; 51(4):2066-2072. PubMed ID: 34013707
[TBL] [Abstract] [Full Text] [Related]
11. Construction and validation of nomograms for predicting the prognosis of grade 3 endometrial endometrioid adenocarcinoma cancers: a SEER-based study.
Liu X; Zhao J; Sun Z; Wang G
Bioengineered; 2021 Dec; 12(1):1752-1765. PubMed ID: 33975518
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas.
Sucu M; Kucukgoz Gulec U; Paydas S; Guzel AB; Kilic Bagir E; Vardar MA
Ginekol Pol; 2021; 92(4):278-283. PubMed ID: 33751504
[TBL] [Abstract] [Full Text] [Related]
13. PRMT5 promotes progression of endometrioid adenocarcinoma via ERα and cell cycle signaling pathways.
Mei S; Ge S; Wang J; Li H; Jing X; Liang K; Zhang X; Xue C; Zhang C; Zhang T
J Pathol Clin Res; 2021 Mar; 7(2):154-164. PubMed ID: 33416213
[TBL] [Abstract] [Full Text] [Related]
14. Is the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma?
Güngördük K; Plett H; Gülseren V; Meydanlı M; Boyraz G; Özdemir İ; Şahin H; Şenol T; Yıldırım N; Turan T; Öge T; Gökçü M; Taşkın S; Ayhan A; Ataseven B
Oncol Res Treat; 2021; 44(1-2):43-51. PubMed ID: 33249415
[TBL] [Abstract] [Full Text] [Related]
15. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Camastra S; Mazzi V; Miccoli M; Benvenga S; Antonelli A
Eur J Endocrinol; 2021 Jan; 184(1):R29-R40. PubMed ID: 33112294
[TBL] [Abstract] [Full Text] [Related]
16. Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway.
Liu HJ; Qin Y; Zhao ZH; Zhang Y; Yang JH; Zhai DH; Cui F; Luo C; Lu MX; Liu PP; Xu HW; Li K; Sun B; Chen S; Zhou HG; Yang C; Sun T
Theranostics; 2020; 10(20):9083-9099. PubMed ID: 32802180
[No Abstract] [Full Text] [Related]
17. Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with ovarian cancer.
Gallardo-Rincón D; Toledo-Leyva A; Bahena-González A; Montes-Servín E; Muñoz-Montaño W; Coronel-Martínez J; Oñate-Ocaña LF
Arch Med Res; 2020 Oct; 51(7):690-699. PubMed ID: 32768148
[TBL] [Abstract] [Full Text] [Related]
18. Utilization and Treatment Patterns of Cytoreduction Surgery and Intraperitoneal Chemotherapy in the United States.
Ellis RJ; Schlick CJR; Yang AD; Barber EL; Bilimoria KY; Merkow RP
Ann Surg Oncol; 2020 Jan; 27(1):214-221. PubMed ID: 31187369
[TBL] [Abstract] [Full Text] [Related]
19. Challenges and controversies in the conservative management of uterine and ovarian cancer.
Janda M; McGrath S; Obermair A
Best Pract Res Clin Obstet Gynaecol; 2019 Feb; 55():93-108. PubMed ID: 30243603
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma.
Mhawech-Fauceglia P; Walia S; Yessaian A; Machida H; Matsuo K; Lawrenson K
Pathology; 2018 Aug; 50(5):499-503. PubMed ID: 29891190
[TBL] [Abstract] [Full Text] [Related]
[Next]
